Myotrophin "Potentially Approvable" Letter Requests More Efficacy Data

A "potentially approvable" letter for Cephalon/Chiron's Myotrophin issued May 12 indicates that the recombinant growth factor protein for the treatment of amyotrophic lateral sclerosis will receive approval only if an ongoing Japanese Phase III trial shows efficacy.